Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB0107 in Healthy Japanese Subjects
NCT03605082Phase 1Completed
- Sponsor
- UCB
- Start
- Jul 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) comparing UCB0107 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events at Day 140, Maximum observed serum concentration at Day 140 and 6 more. Started Jul 2018; status: completed.
02
Drugs
Bepranemab
03
Conditions
Alzheimer's disease (AD)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03605082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605082.